The California Supreme Court ruled on August 3 that Gilead Sciences owed no legal duty to patients to develop and commercialize a newer HIV medication faster than it did, ending years of litigation brought by roughly 24,000 people who took the company's older tenofovir-based drugs.
The decision in the consolidated Gilead Tenofovir Cases came down 6-1, in an opinion written by Justice Joshua Groban. It reverses a 2024 California Court of Appeal ruling that had allowed a novel negligence theory to proceed, one that would have extended a manufacturer's duty of reasonable care beyond the obligation not to sell a defective product.
For patients living with HIV, the practical takeaway is narrow but important. The ruling does not find that either medication was unsafe, and it does not change any prescribing guidance. It answers a question about California tort law: whether a company can be sued for how quickly it moved a different product through development.
The Claim the Court Rejected
The plaintiffs took medicines containing tenofovir disoproxil fumarate, known as TDF, which was approved in 2001 and became a backbone of HIV treatment and prevention. They alleged the drug contributed to kidney and bone injuries.
Critically, they did not argue that TDF was defective in design, manufacturing, or labeling, and they did not seek to remove it from the market. Instead, they alleged Gilead had developed a related compound, tenofovir alafenamide, or TAF, that was similarly effective with a different safety profile, and that the company delayed commercializing it to maximize revenue from TDF before patent protections expired.
Gilead maintained throughout the litigation that the development and commercialization timeline for a future product falls outside its duty of care to users of an approved, non-defective medicine. Dozens of trade groups and companies, including several large drugmakers, filed briefs supporting that position. An analysis by the law firm King & Spalding, published before argument, described how both sides framed the duty-to-innovate theory.
The Reasoning Behind the Decision
The court concluded that imposing a duty of care in this situation would place extraordinary burdens on drug manufacturers and risk distorting research priorities and chilling innovation in ways that could undermine rather than advance public health. Groban also wrote that such a duty would require juries to second-guess complex scientific judgments in hindsight, including where the underlying science was still unsettled.
A central strand of the reasoning concerned what it means to know that an alternative drug is safer. The Court of Appeal had accepted, at the summary judgment stage, that Gilead possessed comparative knowledge based on early trial data. As the full opinion in Gilead Tenofovir Cases explains, that evidence was a single phase I/II study comparing TAF to TDF that lasted two weeks and involved 30 subjects. The majority questioned whether terms such as safer and at least equally effective could be applied meaningfully before a compound completes late-stage testing and secures regulatory approval.
Justice Kelli Evans dissented, describing Gilead's conduct as morally blameworthy and noting that the pharmaceutical industry already benefits from patent protection and from exemptions to strict products liability. She urged the California Legislature to consider eliminating manufacturer immunity from negligence claims of this kind. Groban responded that moral blame was not the issue, given the morally neutral and socially valuable reasons that can underlie drug development decisions. Reuters reported the dissent and the majority's response in detail.
The Effect on Patients Taking These Medications
Nothing in this ruling instructs anyone to change medications. TDF-based regimens remain approved, widely used, and included in treatment and prevention guidelines. TAF-based regimens are also approved and widely used.
Both compounds have documented side effect profiles disclosed in their labeling. Federal guidelines for antiretroviral therapy in adults and adolescents note that TAF carries less bone and kidney toxicity and is therefore preferred for people at risk for those conditions, while TDF is associated with lower lipid levels. Safety, cost, and access all factor into the choice between them.
People taking either medication who have questions about long-term monitoring, bone density, or kidney function should raise them at a scheduled visit. Do not stop an antiretroviral regimen without speaking with the prescribing clinician, because interrupting HIV treatment can allow the virus to rebound and can contribute to drug resistance.
Consequences Beyond This Case
The ruling closes off what industry lawyers had described as a duty-to-innovate theory. Had it survived, the theory would have allowed patients to sue over research and development timing rather than over the product actually sold to them. Industry coverage of the court's reasoning on manufacturer duty of care noted that the outcome was closely watched well beyond pharmaceuticals, since companies in other sectors had also urged reversal.
Because California law is often influential in other states, the reasoning may be cited elsewhere.
Patient advocates who supported the plaintiffs argue the outcome leaves people with fewer options when they believe a company sat on a product. Industry groups argued the opposite, warning that pipeline decisions would become litigation exposure and that companies might avoid generating or disclosing early comparative data at all.
What remains unresolved is whether legislatures will act. The dissent explicitly invited the California Legislature to revisit manufacturer immunity from negligence claims.
Practical Next Steps for Readers
If you are enrolled in HIV care, keep your scheduled laboratory monitoring, including kidney function tests where your clinician has ordered them. If you have experienced bone fractures, unexplained bone pain, or changes in kidney test results while taking a tenofovir-based regimen, bring those records to your next appointment.
If you were a plaintiff in this litigation, contact the attorney who filed on your behalf. This ruling resolves the duty question, but individual case postures may differ.
For people who cannot afford their antiretroviral medications, patient assistance programs, the Ryan White HIV/AIDS Program, and manufacturer copay programs may reduce costs. A clinic social worker or case manager can help identify which apply.
Frequently Asked Questions
What did the court actually decide? That a drug manufacturer does not owe users of a non-defective medicine a legal duty to develop and market a different, allegedly safer compound sooner.
Did the court find TDF unsafe? No. The plaintiffs conceded TDF was not defective. The case was about development timing, not product safety.
Does this change my prescription? No. Both TDF-based and TAF-based regimens remain approved and in use. Any change to your regimen should be discussed with your prescriber.
How many people were involved? Approximately 24,000 plaintiffs who had taken TDF-containing HIV medicines.
Was the decision unanimous? No. It was 6 to 1, with Justice Kelli Evans dissenting and urging legislative review of manufacturer negligence immunity.
Can plaintiffs appeal? The California Supreme Court is the final authority on California state law questions. Further options would be limited and are matters for the plaintiffs' counsel.
What should I watch next? Whether the California Legislature responds to the dissent, and whether courts in other states cite this reasoning in similar claims.
